Biocept, Inc., a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), has announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer.
“Today, patients who are newly diagnosed with epithelial ovarian cancer are treated with a combination of surgery and chemotherapy.” says Raaj Trivedi, vice president of commercial operations for Biocept. “More than 50% of these patients relapse following primary therapy, highlighting the urgent need for novel prognostic indicators of responsiveness to therapy or early indications of recurrence.”
The continuation of this collaboration follows the recent findings from an MD Anderson mouse model study published in the journal Cancer Cell in which Biocept’s OncoCEE testing was utilized. The Company’s OncoCEE microfluidic device captures CTCs and then evaluates the genomic marker, HER3 (human epidermal growth factor receptor 3), for expression on ovarian cancer cells in order to better understand alternative routes of metastasis.
“We believe the findings from this study are valuable as they help in our understanding of ovarian cancer metastasis, and how to improve clinical management of these patients. We are pleased to continue this important research with MD Anderson as they work to enhance the survival rate and lifestyle of ovarian cancer patients,” says Michael Nall, President and CEO of Biocept. Read the study abstract.
Read more
